Cara Therapeutic
Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelike… Read more
Cara Therapeutic (CARA) - Total Liabilities
Latest total liabilities as of December 2024: $48.42 Million USD
Based on the latest financial reports, Cara Therapeutic (CARA) has total liabilities worth $48.42 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cara Therapeutic - Total Liabilities Trend (2011–2024)
This chart illustrates how Cara Therapeutic's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cara Therapeutic Competitors by Total Liabilities
The table below lists competitors of Cara Therapeutic ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suraj Limited
NSE:SURAJLTD
|
India | ₹694.07 Million |
|
NanoCMS Co. Ltd.
KQ:247660
|
Korea | ₩11.97 Billion |
|
KESM Industries Bhd
KLSE:9334
|
Malaysia | RM79.89 Million |
|
Mooncor Oil & Gas Corp
V:MOO
|
Canada | CA$38.27 Million |
|
Wijaya Karya Bangunan Gedung Tbk PT
JK:WEGE
|
Indonesia | Rp2.31 Trillion |
|
Jufan Industrial Co., Ltd.
TWO:4584
|
Taiwan | NT$921.89 Million |
|
Heart Test Laboratories Inc. Common Stock
NASDAQ:HSCS
|
USA | $1.81 Million |
|
Cambium Bio Ltd
AU:CMB
|
Australia | AU$1.46 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Cara Therapeutic's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -10.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cara Therapeutic's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cara Therapeutic (2011–2024)
The table below shows the annual total liabilities of Cara Therapeutic from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $48.42 Million | -29.58% |
| 2023-12-31 | $68.76 Million | +193.12% |
| 2022-12-31 | $23.46 Million | +20.09% |
| 2021-12-31 | $19.53 Million | -11.83% |
| 2020-12-31 | $22.16 Million | -52.09% |
| 2019-12-31 | $46.25 Million | -19.14% |
| 2018-12-31 | $57.19 Million | +459.40% |
| 2017-12-31 | $10.22 Million | -21.97% |
| 2016-12-31 | $13.10 Million | +123.87% |
| 2015-12-31 | $5.85 Million | +37.01% |
| 2014-12-31 | $4.27 Million | -35.00% |
| 2013-12-31 | $6.57 Million | +112.14% |
| 2012-12-31 | $3.10 Million | -32.37% |
| 2011-12-31 | $4.58 Million | -- |